Cyril Amarchand Mangaldas Advised MPS Limited On USD 16.5 Million Acquisition Of Unbound Medicine

Cyril Amarchand Mangaldas advised MPS Limited on USD 16.5M acquisition of Unbound Medicine, a healthcare IT company.

Update: 2026-02-03 08:00 GMT

Cyril Amarchand Mangaldas advised MPS Limited on USD 16.5 Million acquisition of Unbound Medicine

The leading law firm in India, Cyril Amarchand Mangaldas acted as principal counsel to MPS Limited, a publicly listed Indian company, and its subsidiary MPS North America LLC (the “Purchaser”), on the acquisition of 100% of the issued and outstanding capital stock of Unbound Medicine, Inc. (the “Company”) pursuant to a stock purchase agreement executed among the Company, the Purchaser, William M. Detmer, and certain stockholders of the Company. The aggregate consideration for the transaction was USD 16,500,000, subject to customary adjustments. Unbound Medicine is engaged in the business of healthcare and medical information technology.

The CAM transaction was led by Mohit Gogia (Partner), with support from Anisha Dash (Senior Associate), and Muskaan Garg (Associate), Swathi Kathi (Associate), Avikalp Mishra (Associate), and Yash Kataria (Associate).

Click to know more about Cyril Amarchand Mangaldas

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.

Tags:    

Similar News